Literature DB >> 33679690

Ebolavirus: Comparison of Survivor Immunology and Animal Models in the Search for a Correlate of Protection.

Stephanie Longet1, Jack Mellors1, Miles W Carroll1,2, Tom Tipton1.   

Abstract

Ebola viruses are enveloped, single-stranded RNA viruses belonging to the Filoviridae family and can cause Ebola virus disease (EVD), a serious haemorrhagic illness with up to 90% mortality. The disease was first detected in Zaire (currently the Democratic Republic of Congo) in 1976. Since its discovery, Ebola virus has caused sporadic outbreaks in Africa and was responsible for the largest 2013-2016 EVD epidemic in West Africa, which resulted in more than 28,600 cases and over 11,300 deaths. This epidemic strengthened international scientific efforts to contain the virus and develop therapeutics and vaccines. Immunology studies in animal models and survivors, as well as clinical trials have been crucial to understand Ebola virus pathogenesis and host immune responses, which has supported vaccine development. This review discusses the major findings that have emerged from animal models, studies in survivors and vaccine clinical trials and explains how these investigations have helped in the search for a correlate of protection.
Copyright © 2021 Longet, Mellors, Carroll and Tipton.

Entities:  

Keywords:  Ebolavirus; animal models; correlate of protection; survivors; vaccine

Mesh:

Substances:

Year:  2021        PMID: 33679690      PMCID: PMC7935512          DOI: 10.3389/fimmu.2020.599568

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  181 in total

Review 1.  Immunology and evolvement of the adenovirus prime, MVA boost Ebola virus vaccine.

Authors:  Yan Zhou; Nancy J Sullivan
Journal:  Curr Opin Immunol       Date:  2015-08-03       Impact factor: 7.486

2.  Monoclonal Antibody Therapy for Ebola Virus Disease.

Authors:  Myron M Levine
Journal:  N Engl J Med       Date:  2019-11-27       Impact factor: 91.245

3.  The role of the Type I interferon response in the resistance of mice to filovirus infection.

Authors:  Mike Bray
Journal:  J Gen Virol       Date:  2001-06       Impact factor: 3.891

4.  Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group.

Authors:  Raoul J de Groot; Susan C Baker; Ralph S Baric; Caroline S Brown; Christian Drosten; Luis Enjuanes; Ron A M Fouchier; Monica Galiano; Alexander E Gorbalenya; Ziad A Memish; Stanley Perlman; Leo L M Poon; Eric J Snijder; Gwen M Stephens; Patrick C Y Woo; Ali M Zaki; Maria Zambon; John Ziebuhr
Journal:  J Virol       Date:  2013-05-15       Impact factor: 5.103

5.  Modeling pre-existing immunity to adenovirus in rodents: immunological requirements for successful development of a recombinant adenovirus serotype 5-based ebola vaccine.

Authors:  Jin Huk Choi; Stephen C Schafer; Lihong Zhang; Terry Juelich; Alexander N Freiberg; Maria A Croyle
Journal:  Mol Pharm       Date:  2013-08-19       Impact factor: 4.939

6.  Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses.

Authors:  Thomas W Geisbert; Kathleen M Daddario-Dicaprio; Joan B Geisbert; Douglas S Reed; Friederike Feldmann; Allen Grolla; Ute Ströher; Elizabeth A Fritz; Lisa E Hensley; Steven M Jones; Heinz Feldmann
Journal:  Vaccine       Date:  2008-10-18       Impact factor: 3.641

7.  Characterisation of the T-cell response to Ebola virus glycoprotein amongst survivors of the 2013-16 West Africa epidemic.

Authors:  T R W Tipton; Y Hall; J A Bore; A White; L S Sibley; C Sarfas; Y Yuki; M Martin; S Longet; J Mellors; K Ewer; S Günther; M Carrington; M K Kondé; M W Carroll
Journal:  Nat Commun       Date:  2021-02-19       Impact factor: 14.919

8.  Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses.

Authors:  Xiangguo Qiu; Lisa Fernando; Judie B Alimonti; P Leno Melito; Friedericke Feldmann; Daryl Dick; Ute Ströher; Heinz Feldmann; Steven M Jones
Journal:  PLoS One       Date:  2009-05-14       Impact factor: 3.240

9.  Immunogenicity, Lot Consistency, and Extended Safety of rVSVΔG-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults.

Authors:  Scott A Halperin; Rituparna Das; Matthew T Onorato; Kenneth Liu; Jason Martin; Rebecca J Grant-Klein; Rick Nichols; Beth-Ann Coller; Frans A Helmond; Jakub K Simon
Journal:  J Infect Dis       Date:  2019-08-30       Impact factor: 5.226

10.  Longitudinal antibody and T cell responses in Ebola virus disease survivors and contacts: an observational cohort study.

Authors:  Ruth Thom; Thomas Tipton; Thomas Strecker; Yper Hall; Joseph Akoi Bore; Piet Maes; Fara Raymond Koundouno; Sarah Katharina Fehling; Verena Krähling; Kimberley Steeds; Anitha Varghese; Graham Bailey; Mary Matheson; Saidou Kouyate; Moussa Coné; Balla Moussa Keita; Sekou Kouyate; Amento Richard Ablam; Lies Laenen; Valentijn Vergote; Malcolm Guiver; Joseph Timothy; Barry Atkinson; Lisa Ottowell; Kevin S Richards; Andrew Bosworth; Stephanie Longet; Jack Mellors; Delphine Pannetier; Sophie Duraffour; César Muñoz-Fontela; Oumou Sow; Lamine Koivogui; Edmund Newman; Stephan Becker; Armand Sprecher; Herve Raoul; Julian Hiscox; Ana Maria Henao-Restrepo; Keita Sakoba; N'Faly Magassouba; Stephan Günther; Mandy Kader Konde; Miles W Carroll
Journal:  Lancet Infect Dis       Date:  2020-10-13       Impact factor: 71.421

View more
  2 in total

1.  Complement-Mediated Neutralisation Identified in Ebola Virus Disease Survivor Plasma: Implications for Protection and Pathogenesis.

Authors:  Jack Mellors; Tom Tipton; Sarah Katharina Fehling; Joseph Akoi Bore; Fara Raymond Koundouno; Yper Hall; Jacob Hudson; Frances Alexander; Stephanie Longet; Stephen Taylor; Andrew Gorringe; N'Faly Magassouba; Mandy Kader Konde; Julian Hiscox; Thomas Strecker; Miles Carroll
Journal:  Front Immunol       Date:  2022-04-12       Impact factor: 8.786

2.  Molecular Docking and In-Silico Analysis of Natural Biomolecules against Dengue, Ebola, Zika, SARS-CoV-2 Variants of Concern and Monkeypox Virus.

Authors:  Mackingsley Kushan Dassanayake; Teng-Jin Khoo; Chien Hwa Chong; Patrick Di Martino
Journal:  Int J Mol Sci       Date:  2022-09-22       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.